A Phase 2 interventional study of pemetrexed and Best Supportive Care in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-26.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 83rd largest by enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2008, is one of 128 in phase 2, and was the 65th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 72nd largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2008, is one of 73 in phase 2, and was the 59th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer.
A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Drug: pemetrexed · Drug: Best Supportive Care
Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Drug: Best Supportive Care
500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
Also known as: Alimta, LY231514
Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Progression Free Survival During Maintenance Phase
Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.
Time frame: Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months
Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])
Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.
Time frame: First dose of study drug during IP to PD or date of death from any cause up to 33.6 months
Overall Survival During Maintenance Phase
Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.
Time frame: Randomization to PD or date of death from any cause up to 31.3 months
Overall Survival During Overall Period (IP + MP)
Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.
Time frame: First dose of study drug during IP to PD or date of death from any cause up to 34.1 months
Number of Participants With Adverse Events (AEs) During Overall Period
The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.
Time frame: First dose of study drug during IP through overall study completion (up to 34.3) months
Tumor Response Rate and Disease Control Rate After Induction Phase (IP)
Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease \[SD\], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Randomization to measured PD up to 31.4 months
| Milestone | Pemetrexed Plus Cisplatin (Induction Phase) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) |
|---|---|---|---|
| Started | 106 | 0 | 0 |
| Completed | 19 | 0 | 0 |
| Not completed | 87 | 0 | 0 |
| Withdrew: Death | 73 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 | 0 |
| Milestone | Pemetrexed Plus Cisplatin (Induction Phase) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) |
|---|---|---|---|
| Started | 0 | 28 | 27 |
| Completed | 0 | 5 | 10 |
| Not completed | 0 | 23 | 17 |
| Withdrew: Death | 0 | 17 | 15 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 5 | 2 |
Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.
| months | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) |
|---|---|---|
| Progression Free Survival During Maintenance Phase | 3.2 (2.9 to 6.1) | 3.2 (2.2 to 4.3) |
Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.
| months | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) |
|---|---|---|
| Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP]) | 6.2 (6.0 to 8.3) | 6.0 (4.6 to 6.9) |
Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.
| months | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) |
|---|---|---|
| Overall Survival During Maintenance Phase | 12.2 (5.6 to 20.6) | 11.8 (6.3 to 25.6) |
Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.
| months | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) |
|---|---|---|
| Overall Survival During Overall Period (IP + MP) | 15.4 (8.4 to 23.7) | 16.4 (9.1 to 28.5) |
The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.
| participants | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Pemetrexed Plus Cisplatin (Induction Phase) |
|---|---|---|---|
| Adverse Events (AE) | 15 | 16 | 74 |
| Serious Adverse Events (SAE) | 1 | 1 | 13 |
Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease \[SD\], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| percentage of participants | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) |
|---|---|---|
| Best Overall Response Rate | 0 (0.0 to 12.3) | 0 (0.0 to 12.8) |
| CR | 0 (0 to 12.3) | 0 (0 to 12.8) |
| PR | 0 (0.0 to 12.3) | 0 (0.0 to 12.8) |
| SD | 57.1 (37.2 to 75.5) | 44.4 (25.5 to 64.7) |
| Disease Control Rate | 57.1 (37.2 to 75.5) | 44.4 (25.5 to 64.7) |
| PD | 32.1 (15.9 to 52.4) | 37.0 (19.4 to 57.6) |
| Early Death From Malignant Disease | 7.1 (0.9 to 23.5) | 0 (0.0 to 12.8) |
| Early Death From Toxicity | 0 (0.0 to 12.3) | 0 (0.0 to 12.8) |
| Early Death From other cause | 3.6 (0.1 to 18.3) | 0 (0.0 to 12.8) |
| Unknown | 0 (0.0 to 12.3) | 18.5 (6.3 to 38.1) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed Plus Best Supportive Care - Maintenance Phase | — | 1/28 (3.6%) | 15/28 (53.6%) |
| Best Supportive Care - Maintenance Phase | — | 1/27 (3.7%) | 16/27 (59.3%) |
| Pemetrexed + Cisplatin - Induction Phase | — | 13/106 (12.3%) | 74/106 (69.8%) |
| Event | Pemetrexed Plus Best Supportive Care - Maintenance Phase | Best Supportive Care - Maintenance Phase | Pemetrexed + Cisplatin - Induction Phase |
|---|---|---|---|
| Sudden deathGeneral disorders | 0/28 | 1/27 | 2/106 |
| Cardiac arrestCardiac disorders | 1/28 | 0/27 | 0/106 |
| AnaemiaBlood and lymphatic system disorders | 0/28 | 0/27 | 1/106 |
| Acute myocardial infarctionCardiac disorders | 0/28 | 0/27 | 1/106 |
| DeafnessEar and labyrinth disorders | 0/28 | 0/27 | 1/106 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 0/27 | 1/106 |
| VomitingGastrointestinal disorders | 0/28 | 0/27 | 1/106 |
| DeathGeneral disorders | 0/28 | 0/27 | 1/106 |
| Weight decreasedInvestigations | 0/28 | 0/27 | 1/106 |
| Altered state of consciousnessNervous system disorders | 0/28 | 0/27 | 1/106 |
| Event | Pemetrexed Plus Best Supportive Care - Maintenance Phase | Best Supportive Care - Maintenance Phase | Pemetrexed + Cisplatin - Induction Phase |
|---|---|---|---|
| VomitingGastrointestinal disorders | 2/28 | 0/27 | 35/106 |
| Decreased appetiteMetabolism and nutrition disorders | 2/28 | 3/27 | 26/106 |
| FatigueGeneral disorders | 3/28 | 4/27 | 25/106 |
| AnaemiaBlood and lymphatic system disorders | 5/28 | 3/27 | 14/106 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/28 | 4/27 | 10/106 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/28 | 4/27 | 9/106 |
| Chest painGeneral disorders | 4/28 | 3/27 | 8/106 |
| NauseaGastrointestinal disorders | 2/28 | 0/27 | 15/106 |
| NeutropeniaBlood and lymphatic system disorders | 3/28 | 1/27 | 11/106 |
| GastritisGastrointestinal disorders | 2/28 | 1/27 | 8/106 |
| Age Continuous(years) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| Mean | 57.4 ± 12.52 | 62.9 ± 9.97 | 60.1 ± 11.57 |
| Sex: Female, Male(Participants) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| Female | 8 | 10 | 18 |
| Male | 20 | 17 | 37 |
| Race/Ethnicity, Customized(Participants) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| Caucasian | 26 | 26 | 52 |
| African | 2 | 1 | 3 |
| Region of Enrollment(participants) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| Egypt | 24 | 19 | 43 |
| Saudi Arabia | 0 | 1 | 1 |
| Lebanon | 4 | 7 | 11 |
| Pathological Diagnosis(participants) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| Mixed Cell Carcinoma, Lung | 1 | 1 | 2 |
| Large Cells Lung Carcinoma | 8 | 5 | 13 |
| Adenocarcinoma | 19 | 21 | 40 |
| Stage of Disease at The Time of Entry into This Study(participants) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| Stage III B - Locally advanced | 9 | 10 | 19 |
| Stage IV - Metastasized | 19 | 17 | 36 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status at randomization of maintenance phase(participants) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| 0 - Fully active | 6 | 8 | 14 |
| 1 - Ambulatory, restricted strenuous activity | 20 | 17 | 37 |
| 2 - Ambulatory, unable to carry out work activity | 2 | 2 | 4 |
| Lesion Response to induction phase(participants) | Pemetrexed Plus Best Supportive Care (Maintenance Phase) | Best Supportive Care (Maintenance Phase) | Total |
|---|---|---|---|
| Complete Response (CR) | 0 | 1 | 1 |
| Partial Response (PR) | 10 | 11 | 21 |
| Stable Disease (SD) | 17 | 13 | 30 |
| Unknown | 1 | 2 | 3 |
The record gives a start of Jan 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →